Literature DB >> 34230642

Differences among [18F]FDG PET-derived parameters in lung cancer produced by three software packages.

Agnieszka Bos-Liedke1, Paulina Cegla2, Krzysztof Matuszewski3, Ewelina Konstanty3, Adam Piotrowski1, Magdalena Gross1, Julian Malicki3,4, Maciej Kozak1.   

Abstract

Investigation of differences in derived [18F]FDG PET metabolic and volumetric parameters among three different software programs in lung cancer. A retrospective analysis was performed on a group of 98 lung cancer patients who underwent a baseline [18F]FDG PET/CT study. To assess appropriate delineation methods, the NEMA phantom study was first performed using the following software: Philips EBW (Extended Brilliance Workstation), MIM Software and Rover. Based on this study, the best cut-off methods (dependent on tumour size) were selected, extracted and applied for lung cancer delineation. Several semiquantitative [18F]FDG parameters (SUVmax, SUVmean, TLG and MTV) were assessed and compared among the three software programs. The parameters were assessed based on body weight (BW), lean body mass (LBM) and Bq/mL. Statistically significant differences were found in SUVmean (LBM) between MIM Software and Rover (4.62 ± 2.15 vs 4.84 ± 1.20; p < 0.005), in SUVmean (Bq/mL) between Rover and Philips EBW (21,852.30 ± 21,821.23 vs 19,274.81 ± 13,340.28; p < 0.005) and Rover and MIM Software (21,852.30 ± 21,821.23 vs 19,399.40 ± 10,051.30; p < 0.005), and in MTV between MIM Software and Philips EBW (19.87 ± 25.83 vs 78.82 ± 228.00; p = 0.0489). This study showed statistically significant differences in the estimation of semiquantitative parameters using three independent image analysis tools. These findings are important for performing further diagnostic and treatment procedures in lung cancer patients.

Entities:  

Year:  2021        PMID: 34230642     DOI: 10.1038/s41598-021-93436-w

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  34 in total

1.  Feasibility of rapid integrated radiation therapy planning with follow-up FDG PET/CT to improve overall treatment assessment in head and neck cancer.

Authors:  Rustain Morgan; Bennett B Chin; Ryan Lanning
Journal:  Am J Nucl Med Mol Imaging       Date:  2019-02-15

2.  Correlation between two methods of florbetapir PET quantitative analysis.

Authors:  Christopher Breault; Jonathan Piper; Abhinay D Joshi; Sara D Pirozzi; Aaron S Nelson; Ming Lu; Michael J Pontecorvo; Mark A Mintun; Michael D Devous
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-07-15

3.  Assessment of Standardised Uptake Values in PET Imaging Using Different Software Packages.

Authors:  Mario Sansone; Mario Cesarelli; Alessandro Pepino; Paolo Bifulco; Maria Romano; Maria Luisa De Rimini; Pietro Muto
Journal:  J Med Imaging Radiat Sci       Date:  2013-06-22

4.  Image Quality and Diagnostic Performance of a Digital PET Prototype in Patients with Oncologic Diseases: Initial Experience and Comparison with Analog PET.

Authors:  Nghi C Nguyen; Jose L Vercher-Conejero; Abdus Sattar; Michael A Miller; Piotr J Maniawski; David W Jordan; Raymond F Muzic; Kuan-Hao Su; James K O'Donnell; Peter F Faulhaber
Journal:  J Nucl Med       Date:  2015-07-09       Impact factor: 10.057

5.  Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer.

Authors:  Paul De Leyn; Christophe Dooms; Jaroslaw Kuzdzal; Didier Lardinois; Bernward Passlick; Ramon Rami-Porta; Akif Turna; Paul Van Schil; Frederico Venuta; David Waller; Walter Weder; Marcin Zielinski
Journal:  Eur J Cardiothorac Surg       Date:  2014-02-26       Impact factor: 4.191

6.  Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Gerard A Silvestri; Anne V Gonzalez; Michael A Jantz; Mitchell L Margolis; Michael K Gould; Lynn T Tanoue; Loren J Harris; Frank C Detterbeck
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

7.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

8.  FDG-PET/CT findings highly suspicious for COVID-19 in an Italian case series of asymptomatic patients.

Authors:  Lucia Setti; Margarita Kirienko; Serena Camilla Dalto; Manuela Bonacina; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-04-27       Impact factor: 9.236

9.  Comparison of commercial dosimetric software platforms in patients treated with 177 Lu-DOTATATE for peptide receptor radionuclide therapy.

Authors:  Erick Mora-Ramirez; Lore Santoro; Emmanuelle Cassol; Juan C Ocampo-Ramos; Naomi Clayton; Gunjan Kayal; Soufiane Chouaf; Dorian Trauchessec; Jean-Pierre Pouget; Pierre-Olivier Kotzki; Emmanuel Deshayes; Manuel Bardiès
Journal:  Med Phys       Date:  2020-07-31       Impact factor: 4.071

10.  FDG PET/CT for rectal carcinoma radiotherapy treatment planning: comparison of functional volume delineation algorithms and clinical challenges.

Authors:  Nadia Withofs; Claire Bernard; Catherine Van der Rest; Philippe Martinive; Mathieu Hatt; Sebastien Jodogne; Dimitris Visvikis; John A Lee; Philippe A Coucke; Roland Hustinx
Journal:  J Appl Clin Med Phys       Date:  2014-09-08       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.